NASDAQ:AARD

Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Aardvark Therapeutics logo
$0.92 -0.08 (-8.10%)
Closing price 03:57 PM Eastern
Extended Trading
$0.94 +0.02 (+2.07%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Aardvark Therapeutics Stock (NASDAQ:AARD)

Advanced

Key Stats

Today's Range
$0.90
▼
$1.06
50-Day Range
$0.91
▼
$5.75
52-Week Range
$0.90
▼
$16.60
Volume
201,110 shs
Average Volume
362,893 shs
Market Capitalization
$20.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.06
Consensus Rating
Hold

Company Overview

Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance.

The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.

Aardvark’s work centers on developing treatments for metabolic conditions with limited therapeutic options. Its investigational candidates are still in development and are not approved medicines.

AI Generated. May Contain Errors.

Aardvark Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

AARD MarketRank™: 
3.141780821915 of 5 stars

Aardvark Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 293rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aardvark Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, 5 hold ratings, and 2 sell ratings.

  • Upside Potential

    Aardvark Therapeutics has a consensus price target of $11.06, representing about 1,088.2% upside from its current price of $0.93.

  • Amount of Analyst Coverage

    Aardvark Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Aardvark Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aardvark Therapeutics are expected to grow in the coming year, from ($3.17) to ($2.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aardvark Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aardvark Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aardvark Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.78% of the float of Aardvark Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aardvark Therapeutics has a short interest ratio ("days to cover") of 0.38, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aardvark Therapeutics has recently increased by 87.78%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Aardvark Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aardvark Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Aardvark Therapeutics has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Aardvark Therapeutics this week, compared to 8 articles on an average week.
  • Search Interest

    3 people have searched for AARD on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Aardvark Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aardvark Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $394,930.00 in company stock.

  • Percentage Held by Insiders

    17.80% of the stock of Aardvark Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Aardvark Therapeutics has minimal institutional ownership at this time.

  • Read more about Aardvark Therapeutics' insider trading history.
Receive AARD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AARD Stock News Headlines

Your father's savings lost half their value after 1971.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
See More Headlines

AARD Stock Analysis - Frequently Asked Questions

Aardvark Therapeutics' stock was trading at $13.13 at the beginning of 2026. Since then, AARD shares have decreased by 92.9% and is now trading at $0.9310.

Aardvark Therapeutics, Inc. (NASDAQ:AARD) posted its quarterly earnings results on Friday, November, 13th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.19.

Aardvark Therapeutics (AARD) raised $100 million in an initial public offering (IPO) on Friday, February 14th 2025. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets served as the underwriters for the IPO.

Top institutional investors of Aardvark Therapeutics include Marshall Wace LLP (0.60%), State Street Corp (0.26%), Empowered Funds LLC (0.11%) and Ieq Capital LLC (0.05%). Insiders that own company stock include Tien-Li Lee and Nelson Sun.
View institutional ownership trends
.

Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/13/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:AARD
Previous Symbol
NASDAQ:AARD
CIK
1774857
Fax
N/A
Employees
28
Year Founded
2017

Price Target and Rating

High Price Target
$47.00
Low Price Target
$2.00
Potential Upside/Downside
+1,103.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$57.59 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-89.27%
Return on Assets
-80.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.11
Quick Ratio
12.63

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.63 per share
Price / Book
0.35

Miscellaneous

Outstanding Shares
21,890,000
Free Float
17,994,000
Market Cap
$20.12 million
Optionable
Optionable
Beta
4.38

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:AARD) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners